Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Steven A. Edmundowicz MD, MASGE Associate Editor

Scott J. Cotler MD Associate Editor

See All Experts

story of the week

Published in Gastroenterology

Journal Scan / Research · January 21, 2024

Ebastine vs Placebo for the Treatment of Patients With Non-Constipated IBS

Gut

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Prof Robin Spiller MD

Gut

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial

Gut 2024 Jan 08;[EPub Ahead of Print], L Decraecker, D De Looze, DP Hirsch, H De Schepper, J Arts, P Caenepeel, AJ Bredenoord, J Kolkman, K Bellens, K Van Beek, F Pia, W Peetermans, T Vanuytsel, A Denadai-Souza, A Belmans, G Boeckxstaens

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Ebastine vs Placebo for the Treatment of Patients With Non-Constipated IBS

Additional Info

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial

Further Reading

Clinical Practice Update on Management of Nonampullary Duodenal Lesions

MRI and High-Resolution Manometry to Predict Response to Bisacodyl and Hyoscine for Constipation

Association Between Vibration-Controlled Transient Elastography–Based Parameters and Clinical Outcomes in Liver Transplant Recipients

Distinct and Shared Features of Gastroparesis and Functional Dyspepsia

Intensified- vs Standard-Dose Infliximab Induction Therapy for Steroid-Refractory Acute Severe Ulcerative Colitis

Outcomes of an Intervention Combining Energy Restriction and Exercise in Patients With MASH

Clinical Management: Colorectal Intramucosal Carcinoma vs High-Grade Dysplasia and T1 Colorectal Cancer

Liver Transplantation in Patients With Wilson Disease: Current Knowledge and Future Perspectives

Association of Risankizumab Concentration and IL-22 Levels With Clinical and Biochemical Remission of Crohn's Disease

Type, Duration, and Severity of Pre-Transplantation Kidney Injury Predict Prolonged Kidney Dysfunction After Liver Transplantation

Association Between Inflammatory Markers at Birth and the Risk of Early-Onset IBD

Recently Updated